-
1 Comment
Co-Diagnostics, Inc is currently in a long term downtrend where the price is trading 28.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Co-Diagnostics, Inc's total revenue rose by 24903.4% to $27M since the same quarter in the previous year.
Its net income has increased by 974.7% to $15M since the same quarter in the previous year.
Finally, its free cash flow grew by 1282.3% to $19M since the same quarter in the previous year.
Based on the above factors, Co-Diagnostics, Inc gets an overall score of 4/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US1897631057 |
Industry | Medical Devices |
Sector | Healthcare |
Market Cap | 12M |
---|---|
PE Ratio | None |
Beta | 1.21 |
Target Price | 5.5 |
Dividend Yield | None |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CODX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025